Neoadjuvant Durvalumab Shows Benefit in Triple-Negative Breast Cancer
January 3rd 2020David Rimm, MD, PhD, discusses the key takeaways from the results of a phase I/II trial presented in a poster at the 2019 San Antonio Breast Cancer Symposium, which evaluated neoadjuvant checkpoint inhibition in a small subset of patients with triple-negative breast cancer.<br />
Watch
Current Immunotherapy: Progress With Adoptive Cellular Therapies and Combinations
December 27th 2019The clinical development and application of cancer immunotherapy over the past decade has translated the long-standing knowledge of the close relationship between cancerous tissues and lymphoid immune cells, dating back to the late 19th century.
Watch